MCID: ACT009
MIFTS: 52

Acute Monocytic Leukemia

Categories: Cancer diseases, Immune diseases

Aliases & Classifications for Acute Monocytic Leukemia

MalaCards integrated aliases for Acute Monocytic Leukemia:

Name: Acute Monocytic Leukemia 38 12 29 52 14 69
Acute Monoblastic Leukemia and Acute Monocytic Leukemia 12
Acute Monocytic Leukemia Without Mention of Remission 12
M5b Acute Differentiated Monocytic Leukemia 69
Acute Monocytic Leukemia, Morphology 12
Acute Monocytic Leukemia, Fab M5 12
Leukemia, Monocytic, Acute 42

Characteristics:

HPO:

32
acute monocytic leukemia:
Inheritance autosomal dominant somatic cell mutation


Classifications:



External Ids:

Disease Ontology 12 DOID:8864
ICD9CM 35 206.0
MeSH 42 D007948
SNOMED-CT via HPO 65 22331004 413441006
UMLS 69 C0023465

Summaries for Acute Monocytic Leukemia

MalaCards based summary : Acute Monocytic Leukemia, also known as acute monoblastic leukemia and acute monocytic leukemia, is related to hemolytic anemia and adult acute monocytic leukemia. An important gene associated with Acute Monocytic Leukemia is KAT6A (Lysine Acetyltransferase 6A), and among its related pathways/superpathways are Chromatin organization and Chromatin Regulation / Acetylation. The drugs Cytarabine and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include myeloid, monocytes and bone, and related phenotypes are growth/size/body region and embryo

Wikipedia : 72 Acute monocytic leukemia (AMoL, or AML-M5) is considered a type of acute myeloid... more...

Related Diseases for Acute Monocytic Leukemia

Diseases in the Monocytic Leukemia family:

Acute Monocytic Leukemia Adult Acute Monocytic Leukemia
Chronic Monocytic Leukemia Subacute Monocytic Leukemia

Diseases related to Acute Monocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 78)
id Related Disease Score Top Affiliating Genes
1 hemolytic anemia 29.0 FLT3 KMT2A MLLT10 NUP98
2 adult acute monocytic leukemia 12.4
3 acute monoblastic leukemia 11.2
4 monocytic leukemia 10.8
5 leukemia 10.8
6 classic hodgkin lymphoma, lymphocyte-rich type 10.5 FLT3 MPO
7 essential pentosuria 10.5 FLT3 KMT2A
8 acute pre-b-cell lymphoblastic leukemia 10.3 DNMT3A FLT3
9 nevada syndrome 10.3 CREBBP KAT6A
10 molybdenum cofactor deficiency 10.3 EP300 FLT3
11 cholesteatoma 10.3 FLT3 KMT2A MPO
12 preeclampsia/eclampsia 3 10.2 FLT3 KMT2A MPO
13 acute kidney failure 10.2 KMT2A MLLT10 MPO
14 reticulosarcoma 10.1 KAT6A KIAA0100 KMT2A MYH7B
15 familial bicuspid aortic valve 10.0 KMT2A MLLT3
16 spinocerebellar ataxia, autosomal recessive 21 10.0 FLT3 KMT2A MPO
17 idiopathic syringomyelia 10.0 FLT3 MLLT10
18 central nervous system mature teratoma 9.9 FLT3 MPO
19 hunter macpherson syndrome 9.9 CREBBP EP300
20 constricting bands, congenital 9.9 CREBBP EP300
21 lymphoma 9.9
22 sarcoma 9.9
23 histiocytosis 9.9
24 lymphoblastic leukemia 9.8
25 myeloid leukemia 9.8
26 peroxisome biogenesis disorder 5a 9.8 FLT3 KMT2A MLLT10 MPO
27 acute necrotizing encephalopathy 9.8 CREBBP FLT3 KMT2A MPO
28 aleukemic leukemia cutis 9.7
29 respiratory failure 9.7
30 blastic plasmacytoid dendritic cell 9.7
31 gingivitis 9.7
32 germ cells tumors 9.7
33 cytomegalovirus infection 9.7
34 myelodysplastic syndrome 9.7
35 aplastic anemia 9.6
36 pancreatitis 9.6
37 generalized eruptive histiocytosis 9.6
38 nijmegen breakage syndrome 9.6
39 thrombosis 9.6
40 hemoglobinuria 9.6
41 histiocytic sarcoma 9.6
42 multiple myeloma 9.6
43 down syndrome 9.6
44 testicular germ cell tumor 9.6
45 malignant histiocytosis 9.6
46 acute lymphocytic leukemia 9.6
47 chronic lymphocytic leukemia 9.6
48 testicular leukemia 9.6
49 macroglobulinemia 9.6
50 chronic myelomonocytic leukemia 9.6

Graphical network of the top 20 diseases related to Acute Monocytic Leukemia:



Diseases related to Acute Monocytic Leukemia

Symptoms & Phenotypes for Acute Monocytic Leukemia

Human phenotypes related to Acute Monocytic Leukemia:

32
id Description HPO Frequency HPO Source Accession
1 acute monocytic leukemia 32 HP:0004845

MGI Mouse Phenotypes related to Acute Monocytic Leukemia:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.07 AFDN CREBBP DNMT3A EP300 FLT3 KAT6A
2 embryo MP:0005380 10.01 AFDN CREBBP DNMT3A EP300 KAT6A KMT2A
3 hematopoietic system MP:0005397 9.97 CAB39L CREBBP EP300 FLT3 KAT6A KMT2A
4 mortality/aging MP:0010768 9.9 AFDN CREBBP DNMT3A EP300 FLT3 KAT6A
5 immune system MP:0005387 9.86 FLT3 KAT6A KMT2A MLLT3 MPO NUP98
6 neoplasm MP:0002006 9.43 CREBBP EP300 FLT3 KMT2A MLLT3 NME1
7 no phenotypic analysis MP:0003012 9.1 MLLT10 MLLT3 AFDN DNMT3A FLT3 KMT2A

Drugs & Therapeutics for Acute Monocytic Leukemia

Drugs for Acute Monocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 215)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 147-94-4 6253
2
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
3
Mitoxantrone Approved, Investigational Phase 3,Phase 2,Phase 1 65271-80-9 4212
4
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1 55-98-1 2478
5
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
6
Daunorubicin Approved Phase 3,Phase 2,Phase 1 20830-81-3 30323
7
Idarubicin Approved Phase 3,Phase 2,Phase 1,Early Phase 1 58957-92-9 42890
8
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
9
Mesna Approved Phase 3 3375-50-6 598
10
Aldesleukin Approved Phase 3,Phase 1,Phase 2 85898-30-2, 110942-02-4
11
Amsacrine Approved Phase 3 51264-14-3 2179
12
Thioguanine Approved Phase 3,Phase 1 154-42-7 2723601
13
Clofarabine Approved, Investigational Phase 2, Phase 3, Phase 1 123318-82-1 119182
14
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
15
Asparaginase Approved Phase 3,Phase 2,Phase 1 9015-68-3
16
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 1 50-02-2 5743
17
Fludarabine Approved Phase 3,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
18
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754 657311
19
Methotrexate Approved Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
20
Hydroxyurea Approved Phase 3 127-07-1 3657
21
alemtuzumab Approved, Investigational Phase 2, Phase 3,Phase 1 216503-57-0
22
Arsenic trioxide Approved, Investigational Phase 2, Phase 3,Phase 1 1327-53-3 518740
23
Azacitidine Approved, Investigational Phase 2, Phase 3, Phase 1 320-67-2 9444
24
Melphalan Approved Phase 2, Phase 3, Phase 1 148-82-3 4053 460612
25
Carmustine Approved Phase 3 154-93-8 2578
26
Decitabine Approved, Investigational Phase 3,Phase 2,Phase 1 2353-33-5 451668
27
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 468682 2826718
28
Fluconazole Approved Phase 3 86386-73-4 3365
29
Cyproheptadine Approved Phase 3 129-03-3 2913
30
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
31
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 2,Phase 1 302-79-4 5538
32
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
33
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
34
Butyric Acid Experimental Phase 3 107-92-6 264
35
tipifarnib Investigational Phase 2, Phase 3,Phase 1 192185-72-1 159324
36 Staurosporine Experimental Phase 3,Phase 1 62996-74-1
37 Analgesics Phase 3,Phase 2,Phase 1
38 Antibodies Phase 3,Phase 2
39 Antibodies, Monoclonal Phase 3,Phase 2
40 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Early Phase 1
41 Antimetabolites Phase 3,Phase 2,Phase 1,Early Phase 1
42 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Early Phase 1
43 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
44 Antiviral Agents Phase 3,Phase 2,Phase 1,Early Phase 1
45 Etoposide phosphate Phase 3,Phase 2,Phase 1
46 Immunoglobulins Phase 3,Phase 2
47 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Early Phase 1
48 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
49 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Early Phase 1
50 Alkylating Agents Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 187)

id Name Status NCT ID Phase Drugs
1 Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia Unknown status NCT00006045 Phase 3 cytarabine;etoposide;mitoxantrone hydrochloride
2 Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00002549 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mesna;mitoxantrone hydrochloride
3 Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia Unknown status NCT00004128 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide
4 Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia Unknown status NCT00002658 Phase 3 amsacrine;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin
5 Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission Unknown status NCT00454168 Phase 3
6 Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Unknown status NCT00091234 Phase 2, Phase 3 gemtuzumab ozogamicin
7 Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00006363 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar;busulfan
8 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Completed NCT00002798 Phase 3 asparaginase;daunorubicin hydrochloride;fludarabine phosphate;therapeutic hydrocortisone;cytarabine;idarubicin;dexamethasone;thioguanine;etoposide;methotrexate;cyclophosphamide;busulfan
9 Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia Completed NCT00003190 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar
10 Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00369317 Phase 3 asparaginase;daunorubicin hydrochloride;cytarabine;thioguanine;etoposide
11 Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00372593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;etoposide;gemtuzumab ozogamicin;mitoxantrone hydrochloride
12 Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia Completed NCT00005863 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;tretinoin
13 Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00121303 Phase 3 cytarabine;daunorubicin hydrochloride;gemtuzumab ozogamicin
14 Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia Completed NCT00046930 Phase 3 cytarabine;daunorubicin hydrochloride;zosuquidar trihydrochloride;Placebo
15 Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00052299 Phase 3 cytarabine;etoposide;gemtuzumab ozogamicin;idarubicin;mitoxantrone hydrochloride
16 flt3L in Treating Patients With Acute Myeloid Leukemia Completed NCT00006223 Phase 3
17 Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia Completed NCT00112554 Phase 3 cytarabine;laromustine
18 Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
19 Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Completed NCT00454480 Phase 2, Phase 3 arsenic trioxide;azacitidine;busulfan;clofarabine;cytarabine;daunorubicin hydrochloride;fludarabine phosphate;gemtuzumab ozogamicin;melphalan;tipifarnib
20 Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
21 S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML Completed NCT00085709 Phase 3 gemtuzumab ozogamicin;Cytosine arabinoside;Daunomycin
22 Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00002719 Phase 3 amsacrine;carmustine;cytarabine;etoposide;idarubicin;mitoxantrone hydrochloride
23 Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00002517 Phase 3 cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine
24 High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00002945 Phase 3 cyclophosphamide;cytarabine;etoposide;idarubicin;melphalan
25 Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Recruiting NCT02085408 Phase 3 clofarabine;daunorubicin hydrochloride;cytarabine;decitabine
26 Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy Active, not recruiting NCT01307579 Phase 3 caspofungin acetate;fluconazole
27 Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting NCT00651261 Phase 3 cytarabine;daunorubicin;midostaurin;dexamethasone acetate
28 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
29 Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant Unknown status NCT02038153 Phase 1, Phase 2 Lenalidomide
30 Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00003405 Phase 2 amifostine trihydrate;bromodeoxyuridine;cytarabine;idarubicin;idoxuridine;isotretinoin;mitoxantrone hydrochloride
31 Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous Leukemia Unknown status NCT00003758 Phase 2 cytarabine;idarubicin
32 VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia Unknown status NCT00354276 Phase 2 cytarabine;laromustine
33 Monoclonal Antibody in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00006084 Phase 2
34 Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia Unknown status NCT00838240 Phase 1, Phase 2 clofarabine;cytarabine;idarubicin
35 Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Unknown status NCT00425477 Phase 2 bexarotene
36 Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia Completed NCT00666588 Phase 2 idarubicin;cytarabine;bortezomib;etoposide
37 Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Completed NCT00027872 Phase 2 tipifarnib
38 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
39 Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia Completed NCT01870596 Phase 2 Cytarabine;CHK1 Inhibitor SCH 900776
40 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia Completed NCT01361464 Phase 2 Tipifarnib
41 Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed NCT00634244 Phase 2 alvocidib;mitoxantrone hydrochloride;carboplatin;cytarabine;sirolimus;etoposide;topotecan hydrochloride
42 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed NCT01093586 Phase 2 busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
43 Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia Completed NCT02144675 Phase 2 choline magnesium trisalicylate;idarubicin;cytarabine
44 Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00407966 Phase 2 alvocidib;cytarabine;mitoxantrone hydrochloride
45 AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed NCT01253447 Phase 2 Akt inhibitor MK2206
46 Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT01349972 Phase 2 alvocidib;daunorubicin hydrochloride;mitoxantrone hydrochloride;cytarabine
47 S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00093418 Phase 2 tipifarnib
48 Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Completed NCT00742625 Phase 1, Phase 2 daunorubicin hydrochloride;cytarabine;bortezomib
49 Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00795002 Phase 2 alvocidib;mitoxantrone hydrochloride;cytarabine
50 Vorinostat in Treating Patients With Acute Myeloid Leukemia Completed NCT00305773 Phase 2 vorinostat;vorinostat

Search NIH Clinical Center for Acute Monocytic Leukemia

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Acute Monocytic Leukemia cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Acute Monocytic Leukemia:
NiCord
Embryonic/Adult Cultured Cells Related to Acute Monocytic Leukemia:
Umbilical cord blood-derived stem cells (NiCord) PMIDs: 22198152

Cochrane evidence based reviews: leukemia, monocytic, acute

Genetic Tests for Acute Monocytic Leukemia

Genetic tests related to Acute Monocytic Leukemia:

id Genetic test Affiliating Genes
1 Acute Monocytic Leukemia 29

Anatomical Context for Acute Monocytic Leukemia

MalaCards organs/tissues related to Acute Monocytic Leukemia:

39
Myeloid, Monocytes, Bone, Bone Marrow, Lung, Prostate, Skin

Publications for Acute Monocytic Leukemia

Articles related to Acute Monocytic Leukemia:

(show top 50) (show all 263)
id Title Authors Year
1
Upregulation of long non-coding RNA MALAT-1 confers poor prognosis and influences cell proliferation and apoptosis in acute monocytic leukemia. ( 28713913 )
2017
2
Cordycepin induces apoptosis of human acute monocytic leukemia cells via downregulation of the ERK/Akt signaling pathway. ( 28912858 )
2017
3
5a89azaa892'a89deoxycytidine promotes migration of acute monocytic leukemia cells via activation of CCL2a89CCR2a89ERK signaling pathway. ( 28627644 )
2017
4
Lineage switch from B acute lymphoblastic leukemia to acute monocytic leukemia with persistent t(4;11)(q21;q23) and cytogenetic evolution under CD19-targeted therapy. ( 28634616 )
2017
5
Bone Marrow Adipocytes Facilitate Fatty Acid Oxidation Activating AMPK and a Transcriptional Network Supporting Survival of Acute Monocytic Leukemia Cells. ( 28108519 )
2017
6
Cutaneous presentation preceding acute monocytic leukemia: A CARE-compliant article. ( 28272239 )
2017
7
Characterization of an acquired jumping translocation involving 3q13.31-qter in a patient with de novo acute monocytic leukemia. ( 28625614 )
2017
8
Duplication of subtelomeric regions in an adult with acute monocytic leukemia with an acquired jumping translocation involving 3q13.31-qter. ( 28725672 )
2017
9
Jab1/Csn5-Thioredoxin Signaling in Relapsed Acute Monocytic Leukemia under Oxidative Stress. ( 28270496 )
2017
10
Knockdown of p54nrb inhibits migration, invasion and TNF-I+ release of human acute monocytic leukemia THP1 cells. ( 27108701 )
2016
11
Leukemia cutis preceding bone marrow relapse in acute monocytic leukemia. ( 27643547 )
2016
12
Acute Monocytic Leukemia Masquerading BehAset's Disease-Like Illness at Onset in an Elderly Female. ( 27610252 )
2016
13
The Successful Complete Remission Induction by Sorafenib Monotherapy in a FLT3-D835Y-Positive Patient with Refractory Acute Monocytic Leukemia. ( 27408351 )
2016
14
Suppression of NRF2-ARE activity sensitizes chemotherapeutic agent-induced cytotoxicity in human acute monocytic leukemia cells. ( 26708503 )
2016
15
Hypoxia inducible factor-1a regulates a pro-invasive phenotype in acute monocytic leukemia. ( 27447550 )
2016
16
Polydatin Induces Apoptosis and Inhibits Growth of Acute Monocytic Leukemia Cells. ( 26616494 )
2016
17
Generation of a MLL-AF9-specific stem cell model of acute monocytic leukemia. ( 27185517 )
2016
18
Histiocytic differentiation in acute monocytic leukemia. ( 26771450 )
2016
19
Spurious Thrombocytosis Caused by Tumor Cell Lysis in a Patient with Acute Monocytic Leukemia. ( 28164618 )
2016
20
Acute monocytic leukemia masked by hemolytic anemia and sclerotic lesions. ( 27572458 )
2016
21
Ara-C and anti-CD47 antibody combination therapy eliminates acute monocytic leukemia THP-1 cells in vivo and in vitro. ( 26125761 )
2015
22
A case of extramedullary involvement of acute monocytic leukemia that presented as obstructive jaundice. ( 26422978 )
2015
23
Induction with azacytidine followed by allogeneic hematopoietic stem cell transplantation in a Jehovah's Witness with acute monocytic leukemia. ( 25984306 )
2015
24
Autocrine motility factor receptor promotes the proliferation of human acute monocytic leukemia THP-1 cells. ( 26136223 )
2015
25
Nitric oxide is the key mediator of death induced by fisetin in human acute monocytic leukemia cells. ( 25973292 )
2015
26
Histiocytic sarcoma combined with acute monocytic leukemia: a case report. ( 26187047 )
2015
27
Secondary acute monocytic leukemia positive for 11q23 rearrangement in Nijmegen breakage syndrome. ( 24619942 )
2014
28
Posterior reversible encephalopathy syndrome following acute pancreatitis during chemotherapy for acute monocytic leukemia. ( 24881921 )
2014
29
Severe aplastic anemia preceding acute monocytic leukemia in an adult with acquired trisomy 21: A case report. ( 24396488 )
2014
30
Spontaneous regression of cutaneous blastic plasmacytoid dendritic cell neoplasm followed by acute monocytic leukemia evolving from myelodysplastic syndrome. ( 25447656 )
2014
31
Regulated cellular exposure to non-thermal plasma allows preferentially directed apoptosis in acute monocytic leukemia cells. ( 23400198 )
2013
32
Antiproliferative activities of lesser galangal (Alpinia officinarum Hance Jam1), turmeric (Curcuma longa L.), and ginger (Zingiber officinale Rosc.) against acute monocytic leukemia. ( 23819642 )
2013
33
Bryostatin 5 induces apoptosis in acute monocytic leukemia cells by activating PUMA and caspases. ( 24036350 )
2013
34
Leukemia cutis in a patient with acute monocytic leukemia diagnosed simultaneously with hepatocellular carcinoma: A case study. ( 24179516 )
2013
35
Sorting, identification and enrichment of side population cells in THP-1 acute monocytic leukemia cells. ( 23450319 )
2013
36
Citrate induces apoptosis of the acute monocytic leukemia U937 cell line through regulation of HIF-1I+ signaling. ( 24064771 )
2013
37
Fatal bronchial invasion of Scopulariopsis brevicaulis in an acute monocytic leukemia patient. ( 22633337 )
2012
38
Heterogeneous leukemic clones identified by NPM1 mutation analysis in patient with acute monocytic leukemia. ( 22035378 )
2012
39
A parasite rescue and transformation assay for antileishmanial screening against intracellular Leishmania donovani amastigotes in THP1 human acute monocytic leukemia cell line. ( 23299097 )
2012
40
Jumping translocations of 3q21 in an acute monocytic leukemia (M5) patient reveal mechanisms of multistage telomere shortening in pathogenesis of AML. ( 21983177 )
2012
41
Effect of RNAi-induced down regulation of nuclear factor kappa-B p65 on acute monocytic leukemia THP-1 cells in vitro and vivo. ( 21901538 )
2012
42
Mutations inDNMT3A and loss of RKIP are independent events in acute monocytic leukemia. ( 22875620 )
2012
43
Leukemic manifestation of blastic plasmacytoid dendritic cell neoplasm lacking skin lesion : a borderline case between acute monocytic leukemia. ( 23037626 )
2012
44
Role of misfolded N-CoR mediated transcriptional deregulation of Flt3 in acute monocytic leukemia (AML)-M5 subtype. ( 22514634 )
2012
45
Iron chelation therapy with deferasirox induced complete remission in a patient with chemotherapy-resistant acute monocytic leukemia. ( 21617233 )
2011
46
Capsaicin attenuates palmitate-induced expression of macrophage inflammatory protein 1 and interleukin 8 by increasing palmitate oxidation and reducing c-Jun activation in THP-1 (human acute monocytic leukemia cell) cells. ( 21745629 )
2011
47
Quantitative assessment of MLAA-34 expression in diagnosis and prognosis of acute monocytic leukemia. ( 21240483 )
2011
48
Acute monocytic leukemia blasts with cuplike nuclear morphology: a case report. ( 21299341 )
2011
49
Curcumin blocks Kv11.1 (erg) potassium current and slows proliferation in the infant acute monocytic leukemia cell line THP-1. ( 22179005 )
2011
50
Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. ( 21399634 )
2011

Variations for Acute Monocytic Leukemia

Copy number variations for Acute Monocytic Leukemia from CNVD:

7 (show all 23)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 21832 1 16200000 20400000 Gain Acute monocytic leukemia
2 31525 1 28000000 30200000 Gain Acute monocytic leukemia
3 61776 12 10100000 12800000 Loss Acute monocytic leukemia
4 90243 15 20700000 25700000 Gain Acute monocytic leukemia
5 93369 15 52900000 59100000 Gain Acute monocytic leukemia
6 108855 17 23200000 28800000 Deletion NF1 Acute monocytic leukemia
7 110292 17 31800000 38100000 Gain Acute monocytic leukemia
8 116498 17 67100000 70900000 Loss Acute monocytic leukemia
9 125458 19 13900000 20000000 Gain Acute monocytic leukemia
10 133734 19 6900000 13900000 Gain Acute monocytic leukemia
11 140901 2 203300000 204900000 Loss Acute monocytic leukemia
12 188152 4 59500000 66600000 Loss Acute monocytic leukemia
13 190404 4 88000000 93700000 Loss Acute monocytic leukemia
14 191655 5 1 4500000 Gain Acute monocytic leukemia
15 196530 5 168500000 172800000 Gain Acute monocytic leukemia
16 201329 5 68400000 73300000 Gain Acute monocytic leukemia
17 206333 6 139000000 142800000 Loss Acute monocytic leukemia
18 219029 7 121100000 123800000 Loss Acute monocytic leukemia
19 224721 7 37200000 43300000 Loss Acute monocytic leukemia
20 226783 7 61700000 67000000 Loss Acute monocytic leukemia
21 226785 7 61700000 77500000 Loss Acute monocytic leukemia
22 243519 8 84600000 86900000 Gain Acute monocytic leukemia
23 250024 9 19900000 25600000 Loss Acute monocytic leukemia

Expression for Acute Monocytic Leukemia

Search GEO for disease gene expression data for Acute Monocytic Leukemia.

Pathways for Acute Monocytic Leukemia

GO Terms for Acute Monocytic Leukemia

Cellular components related to Acute Monocytic Leukemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.28 AFDN CREBBP DNMT3A EP300 KAT6A KMT2A
2 histone acetyltransferase complex GO:0000123 8.96 CREBBP EP300

Biological processes related to Acute Monocytic Leukemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.62 CREBBP EP300 KAT6A KMT2A
2 rhythmic process GO:0048511 9.54 CREBBP EP300 KMT2A
3 regulation of cellular response to heat GO:1900034 9.43 CREBBP EP300 NUP98
4 DNA methylation GO:0006306 9.4 DNMT3A KMT2A
5 histone acetylation GO:0016573 9.33 CREBBP EP300 KAT6A
6 N-terminal peptidyl-lysine acetylation GO:0018076 8.96 CREBBP EP300
7 protein acetylation GO:0006473 8.8 CREBBP EP300 KAT6A

Molecular functions related to Acute Monocytic Leukemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 transferase activity GO:0016740 9.87 CREBBP DNMT3A EP300 FLT3 KAT6A KMT2A
2 histone acetyltransferase activity GO:0004402 9.43 CREBBP EP300 KAT6A
3 chromatin binding GO:0003682 9.35 CREBBP DNMT3A EP300 KMT2A MPO
4 peptide N-acetyltransferase activity GO:0034212 9.16 CREBBP EP300
5 lysine-acetylated histone binding GO:0070577 9.07 KMT2A
6 acetyltransferase activity GO:0016407 8.8 CREBBP EP300 KAT6A

Sources for Acute Monocytic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....